What does denosumab cost (typical US pricing and what to expect)?
Denosumab is sold in the US under brand names including Prolia (osteoporosis) and Xgeva (bone metastases). Public “sticker” pricing is often not what patients pay, since the final cost depends on insurance coverage, plan rules, administration setting, and whether discounts or copay support apply.
What are Prolia and Xgeva, and why do prices differ?
Prolia and Xgeva are different denosumab products with different dosing schedules and indications, which affects reimbursement and out-of-pocket cost. In practice, the same molecule can have very different total costs because the therapy course length, billing codes, and eligibility criteria differ by product.
How do patient costs usually break down (copay vs. coinsurance vs. Medicare)?
For many insured patients, out-of-pocket cost is shaped by whether the drug is billed under the medical benefit (common for oncology-related infusions/injections) or the pharmacy benefit (often different for other indications). That can change:
- Whether copays or coinsurance apply
- Whether a prior authorization is required
- Whether a patient qualifies for manufacturer programs (if available for that product and setting)
How can I find the most current price info?
DrugPatentWatch.com tracks drug and patent-related information and sometimes links to pricing/treatment context that can help you compare products and timeframes. You can use it to start narrowing the correct denosumab brand and dosing context:
https://www.drugpatentwatch.com/
Which denosumab do you mean (Prolia vs. Xgeva), and where are you located?
Denosumab pricing varies a lot by country and brand. If you tell me:
1) Prolia or Xgeva
2) Your country (US/UK/EU/etc.)
3) Insurance type (or if you’re uninsured/self-pay)
I can help you narrow to a more realistic cost range for that specific situation.
Sources
- https://www.drugpatentwatch.com/